Co-Diagnostics (C970) Price & Analysis

0 Followers

C970 Stock Chart & Stats

€5.16

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€5.16

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€5.16 - €36.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€6.87M

Enterprise Value€11.51

Total Cash (Recent Filing)€3.65M

Total Debt (Recent Filing)€1.80M

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Nov 05, 2026

EPS Estimate

-1.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-26.72

Shares Outstanding7,141,423

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.33

Price to Sales (P/S)10.83

P/FCF Ratio-0.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.44

Price Target Upside-33.25% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-10.36

Revenue Forecast (FY)€471.11K

Bulls Say, Bears Say

Bulls Say

Regulatory And Clinical Pipeline ProgressThe completed analytical work, sizable clinical enrollment, and dual FDA submission represent meaningful progress toward commercializing a multiplex respiratory assay. Regulatory advancement can broaden the addressable market and improve platform credibility, although approval and revenue conversion remain ahead.

Integrated Platform And International ExpansionCombining PCR technology, a mobile application, and secure cloud infrastructure may strengthen Co-Diagnostics’ ability to support decentralized testing at scale. Deployment in India also creates a foundation for recurring platform, assay, and consumables demand if clinical and regulatory milestones are achieved.

Low Financial LeverageModest debt reduces interest and refinancing pressure compared with a highly leveraged balance sheet, preserving some flexibility while the company pursues product commercialization. This benefit is tempered by the sharply reduced equity base and does not eliminate the need to fund ongoing operating losses.

Bears Say

Collapsed Revenue And Weak ProfitabilityThe severe revenue contraction shows that prior demand has not translated into a stable commercial base. Very low gross margin and losses that remain large relative to sales indicate substantial operating underabsorption, making a durable return to profitability dependent on successful commercialization.

Persistent Cash Burn And Shrinking LiquidityOngoing operating and free-cash-flow deficits are consuming the company’s available resources while cash has fallen materially. With management expecting continued near-term losses, limited liquidity could constrain clinical, regulatory, and commercial execution unless additional funding is secured.

Financing And Dilution RiskThe financing provides needed corporate funds but increases the share count substantially and adds new five-year warrants. Dependence on equity-linked capital can dilute existing holders and leave future growth plans tied to continued investor access while the business remains loss-making.

Co-Diagnostics News

Co-Diagnostics launches cloud, mobile infrastructure in India

Co-Diagnostics (CODX) announced the launch of its integrated cloud infrastructure in India. The deployment is intended to support...

7d ago

CODX

Co-Diagnostics announces first international deployment of Vector Smart

Co-Diagnostics (CODX) announced the first international deployment of its Vector Smart mosquito surveillance platform, to include shipments of...

9d ago

CODX

Co-Diagnostics files to sell 3.4M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up...

17d ago

CODX

Twelve option delistings on August 24th

Option delistings effective August 24th include ClearSign Combustion (CLIR), Co-Diagnostics (CODX), CRA International (CRAI), Harvard Bioscience (HBIO), Mattersight...

17d ago

RPT

SMX

Co-Diagnostics Appoints New Principal Financial Officer

The latest announcement is out from Co-Diagnostics ( ($CODX) ). On September 2, 2026, Co-Diagnostics, Inc. announced that...

6d ago

CODX

Co-Diagnostics Adjourns Annual Meeting, Sets New Date

Co-Diagnostics ( ($CODX) ) just unveiled an announcement. Co-Diagnostics, Inc. held its previously announced Annual Meeting of Stockholders...

6d ago

CODX

DFTX, ANF, BBWI, DUOL, CODX: Trending By Analysts

Analysts are intrested in these 5 stocks: ( ($DFTX) ), ( ($ANF) ), ( ($BBWI) ), ( ($DUOL)...

19d ago

ANF

BBWI

Co-Diagnostics Earnings Call: Progress Amid Cash Strain

Co-Diagnostics (($CODX)) has held its Q2 earnings call. Read on for the main highlights of the call. Co-Diagnostics’...

19d ago

CODX

Co-Diagnostics submits FDA 510(k) premarket notification for Co-Dx PCR Flu test

Co-Diagnostics (CODX) announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by...

1M ago

CODX

Co-Diagnostics Inducement Agreement for New Warrant Financing

Co-Diagnostics ( ($CODX) ) has shared an update. On July 30, 2026, Co-Diagnostics entered into an inducement agreement...

1M ago

CODX

Co-Diagnostics joint venture CoSara provides ebola test kits for India studies

Co-Diagnostics (CODX) announced that CoSara Diagnostics, the company’s joint venture in India, has sent test kits of the...

1M ago

CODX

Co-Diagnostics Amends Equity Distribution, Extends Issuance Limits

Co-Diagnostics ( ($CODX) ) just unveiled an announcement. On July 27, 2026, Co-Diagnostics amended its October 20, 2025...

1M ago

CODX

Co-Diagnostics appoints Wes Lindsey as Chief Scientific Officer

Co-Diagnostics (CODX) appointed Wes Lindsey as its new Chief Scientific Officer. Lindsey holds a PhD in Genetics &...

2M ago

CODX

CDC raises Ebola Congo outbreak response to highest level, Reuters reports

The Centers for Disease Control raised its response to the Ebola outbreak in the Democratic Republic of Congo...

3M ago

CODX

GOVX

C970 FAQ

What was Co-Diagnostics Inc’s price range in the past 12 months?

Co-Diagnostics Inc lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.

What is Co-Diagnostics Inc’s market cap?

Co-Diagnostics Inc’s market cap is €6.87M.

When is Co-Diagnostics Inc’s upcoming earnings report date?

Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 56 days.

How were Co-Diagnostics Inc’s earnings last quarter?

Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -€1.254 earnings per share for the quarter.

Is Co-Diagnostics Inc overvalued?

According to Wall Street analysts Co-Diagnostics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Co-Diagnostics Inc pay dividends?

Co-Diagnostics Inc does not currently pay dividends.

What is Co-Diagnostics Inc’s EPS estimate?

Co-Diagnostics Inc’s EPS estimate is -1.07.

How many shares outstanding does Co-Diagnostics Inc have?

Co-Diagnostics Inc has 7,141,423 shares outstanding.

What happened to Co-Diagnostics Inc’s price movement after its last earnings report?

Co-Diagnostics Inc reported an EPS of -€1.254 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Co-Diagnostics Inc?

Currently, no hedge funds are holding shares in DE:C970

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Co-Diagnostics Inc

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Co-Diagnostics (C970) Earnings & Revenues

Historic Earnings Reports

C970 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all DE:C970 earnings summaries

C970 Stock 12 Month Forecast

Average Price Target

€3.44

▼(-33.25% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","7":"€7","12":"€12","4.5":"€4.5","9.5":"€9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.44444244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€3.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.44444244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.44444244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.028034033846154,4.896068067692307,4.7641021015384615,4.6321361353846155,4.50017016923077,4.368204203076923,4.236238236923077,4.104272270769231,3.9723063046153846,3.840340338461538,3.7083743723076923,3.576408406153846,{"y":3.44444244,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.028034033846154,4.896068067692307,4.7641021015384615,4.6321361353846155,4.50017016923077,4.368204203076923,4.236238236923077,4.104272270769231,3.9723063046153846,3.840340338461538,3.7083743723076923,3.576408406153846,{"y":3.44444244,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.028034033846154,4.896068067692307,4.7641021015384615,4.6321361353846155,4.50017016923077,4.368204203076923,4.236238236923077,4.104272270769231,3.9723063046153846,3.840340338461538,3.7083743723076923,3.576408406153846,{"y":3.44444244,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.799,"date":1756674000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.16,"date":1759266000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1772316000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1774990800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1777582800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1780261200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1782853200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >